Sign up here for our daily coronovirus newsletter that you need to know, and Subscribe to our Kovid-19 podcast for the latest news and analysis.
Johnson & Johnson will spend approximately $ 604 million expanding its deal with the US government to develop the Kovid-19 vaccine, which will try to catch rivals who are ahead in the race.
The Biomedical Advanced Research and Development Authority will pay approximately $ 454 million in additional funding for the Phase 3 Ensemble Trial, which seeks to evaluate the efficacy of the company’s vaccine candidate as a single dose.
Johnson & Johnson is in the hunt for pharmaceutical companies to develop a Kovid-19 vaccine. Top contender Pfizer Inc. and its partners Biotech SE Announced this week that his vaccine appears to prevent 90% of Kovid infections.
J&J has nominated only a few thousand participants in its 60,000-person trial, partly because it The study halted in October for two weeks over a safety concern. It is now expected that by the end of 2020, there will be an initial readout of the results from the test early next year instead.
A statement on Saturday said, “Combined with our own significant investment, the agreement has enabled our significant research and development and underscored the importance of public-private partnerships to combat the Kovid-19 epidemic worldwide. Has done, ”Jeff J. Chief Scientific Officer said in a statement on Saturday.
Service To speed up the recruitment of participants and cut the test time in half, J & J also has Data turned on experts UnitedHealth Group Inc
J&J and Barda, under the US Department of Health and Human Services, have already committed over $ 1 billion In March for cooperation in dividing the research around 50-50. Pfizer and Bayonet received funding from the German government, not the US, although the Americans would First in line to get 100 million doses.
Read more: Serious Kovid-19 vaccine and treatment data are only days away
(Update with background on test)